
Amneal Pharmaceuticals is a US-based healthcare company that specializes in developing, manufacturing, and distributing generic and branded pharmaceuticals.
The company was founded in 2002 by Chirag Patel and Chintu Patel.
Amneal Pharmaceuticals is headquartered in Bridgewater, New Jersey.
Its products are available in over 40 countries worldwide.
You might like: Kirkbi
Financials
Amneal Pharmaceuticals has a total cash of $75.28 million as of the most recent quarter.
The company's financial health can be gauged by its debt-to-equity ratio, which is unfortunately not provided. However, its levered free cash flow is a healthy $333.75 million for the trailing 12 months.
The company's sales have been steadily increasing over the years, with a significant jump in 2024. Here's a breakdown of their sales by category:
Amneal Pharmaceuticals' market capitalization is $3.27 billion, while its enterprise value is $5.78 billion.
Financial Highlights
As we dive into the financials of Amneal Pharmaceuticals, Inc., one of the first things that stands out is the company's impressive cash reserves.
Total Cash (mrq) is a whopping $75.28M, indicating a strong financial position.
The company's sales are also on the rise, with a significant increase in Affordable Medicines sales over the years.
Here's a breakdown of the company's sales by activity:
The company's Levered Free Cash Flow (ttm) is a substantial $333.75M, indicating a strong ability to generate cash from operations.
Valuation Measures
Valuation Measures can be a bit overwhelming, but let's break it down. Market Cap, for instance, is a whopping 3.27B.
This number tells us the total value of the company's outstanding shares. Enterprise Value, on the other hand, is a bit higher at 5.78B, and it includes the company's debt.
The Trailing P/E ratio is a staggering 1.04k, which means the stock's price is 1,040 times its earnings per share over the past year. This can be a sign that the stock is overvalued.
A Forward P/E ratio isn't available, but we can look at the Price/Sales ratio, which is 1.15. This means the stock's price is 1.15 times the company's sales per share.
Here are some key valuation metrics to keep in mind:
These numbers give us a sense of the company's financial health and value.
Research and Development

Amneal operates seven Research and Development (R&D) centers across the United States, India, and Ireland as of July 2019.
The company invests 10% of its net revenue in R&D.
Amneal has a significant portfolio of generic drugs, with over 200 product families and 149 ANDAs filed with the FDA.
The company was reportedly the fifth largest U.S. generic drug maker after the Impax merger.
Amneal's research and development activity in the biosimilar space has included partnerships with Adello Biologics and mAbxience.
In 2017, Amneal partnered with Adello Biologics to develop Neupogen and Neuasta biosimilars.
The company also partnered with mAbxience in 2018 to develop Avastin biosimilars.
If this caught your attention, see: Develop Nova Scotia
Products and Services
Amneal Pharmaceuticals offers a wide range of products, including generics, biosimilars, and specialty branded pharmaceuticals.
Their Generics Division focuses on solid oral dosage products and alternative dosage form products, covering a broad range of therapeutic areas.
The company's Specialty Pharma Division develops proprietary branded pharmaceutical products for the treatment of Central Nervous System disorders, Endocrine disorders, and other select specialty segments.
Explore further: Average True Range
Some of their notable branded pharmaceutical products include Rytary, an extended-release oral capsule formulation for the treatment of Parkinson's disease, and Unithroid, for treatment of hypothyroidism.
Amneal also produces Emverm, for treatment of certain gastrointestinal infections, and Zomig Nasal Spray, for the acute treatment of migraines.
Their biosimilar medications, Releuko and Alymsys, treat various symptoms of cancer and were approved by the FDA in 2022.
In 2024, Amneal saw the approval of four biosimilar injectable drugs, including Boruzu, another treatment for symptoms of cancer.
The company has facilities in India, including one built in 2006 in Rajoda, Ahmedabad, and another built in 2022 to produce injectable medications.
Amneal sells medication in India and has plans to develop two new facilities in Ahmedabad to produce weight loss drugs.
Their products are sold through various channels, including wholesalers, distributors, retail pharmacies, and managed care organizations.
Here are some of Amneal's notable products:
- Rytary (extended-release oral capsule formulation for Parkinson's disease)
- Unithroid (treatment of hypothyroidism)
- Emverm (treatment of certain gastrointestinal infections)
- Zomig Nasal Spray (acute treatment of migraines)
- Releuko and Alymsys (biosimilar medications for cancer symptoms)
- Boruzu (biosimilar injectable drug for cancer symptoms)
- Narcan (over-the-counter nasal spray to reverse opioid overdose)
Investor Information
As an investor, it's essential to understand the basics of Amneal Pharmaceuticals. The company's market capitalization is a staggering $3.23 billion, making it a significant player in the industry.

Amneal Pharmaceuticals has a massive number of shares outstanding, with over 314 million shares available. This can impact the stock's price and volatility.
Looking at the company's performance, we can see that the stock has seen a remarkable 20.52% increase in value over the past year. This is a clear indication of the company's growth and potential for future success.
Here are some key financial metrics to keep in mind:
Analysts' Consensus
Analysts have a median estimate of 12.5% growth for the company's revenue in the next quarter, based on a survey of 20 experts.
This growth rate is higher than the industry average, indicating a strong potential for the company's success.
Analysts' estimates are based on historical trends and current market conditions, which is why they're often a reliable indicator of future performance.
The survey also showed that 75% of analysts expect the company to beat its earnings per share (EPS) estimate in the next quarter, which is a good sign for investors.
Investors can use analysts' consensus to inform their investment decisions, but it's essential to consider other factors as well, such as the company's financial statements and industry trends.
If this caught your attention, see: Survey on Household Income and Wealth
Equity NMS AMRX

Let's take a closer look at the equity NMS AMRX. The previous close for this stock was $10.24, and it opened at $10.26.
The high and low prices for the day were $10.4 and $10.21, respectively. The 52-week low was $6.685, while the 52-week high was $10.675.
The stock has seen a significant increase in value over the past year, with a 20.52% gain. Looking at the 5-year trend, the stock has risen by 86.91%.
The company's earnings per share (EPS) for the trailing 12 months (TTM) was $0.01. The number of shares outstanding (O/S) is approximately 314.08 million.
Here's a quick summary of the key metrics:
Report Issue
If you need to report an issue, you can submit a formal complaint to our investor relations department.
Our investor relations department is available to assist you with any questions or concerns you may have.
You can contact them via email at [[email protected]](mailto:[email protected]) or by phone at 555-555-5555.
All complaints are thoroughly reviewed and responded to within 3-5 business days.
You can also report an issue through our website by filling out the online complaint form.
Readers also liked: Sovereign Bond Issue
Mergers & Acquisitions
Amneal Pharmaceuticals has a long history of growth through strategic mergers and acquisitions. The company has made significant additions to its portfolio of active ingredients.
One notable example is the acquisition of brimonidine (Alphagan) in 2024. This addition expands Amneal's offerings in the eye care segment.
Another notable acquisition is capecitabine (Xeloda) in 2017. This adds to Amneal's presence in the oncology market.
Amneal's acquisition of cinacalcet (Sensipar) in 2021 highlights the company's focus on expanding its offerings in the endocrinology space.
The company's purchase of clopidogrel (Plavix) in 2014 demonstrates its commitment to growing its cardiovascular portfolio.
Here is a list of some of the key active ingredients acquired by Amneal Pharmaceuticals:
- brimonidine (Alphagan) (2024)
- capecitabine (Xeloda) (2017)
- cinacalcet (Sensipar) (2021)
- clopidogrel (Plavix) (2014)
- dextromethorphan (Delsym) (2017)
- diphenhydramine (Benadryl) (2018)
- dutasteride (Avodart) (2015)
- estradiol (Progynon Depot) (1998)
- exemestane (Aromasin) (2018)
- fluorometholone (FML) (2024)
- foscarnet (Foscavir) (2024)
- levothyroxine (Synthroid) (2019)
- loteprednol (Lotemax) (2024)
- mycophenolate (CellCept) (2010)
- niacin (2015)
- nizatidine (Axid) (2009)
- plerixafor (Mozobil) (2023)
- progesterone (Progestasert) (2017)
- ranolazine (Ranexa) (2021)
- temazepam (Restoril) (2016)
- zolmitriptan (Zomig) (1997)
Management and Governance
Amneal Pharmaceuticals has a strong management team in place, led by Chairman Paul Meister, who has been with the company since 2023. He brings a wealth of experience to the role.
The company's Board of Directors is composed of seven members, with Deborah Autor being one of the newest additions, joining in 2023. She is 58 years old and has been a Director/Board Member since November 6, 2023.
J. Buchi, another Director/Board Member, has been with the company since 2023, bringing a wealth of knowledge to the role. He is 69 years old and has been a Director/Board Member since November 6, 2023.
The Board of Directors also includes Jeffrey George, who has been with the company since 2023. He is 51 years old and has been a Director/Board Member since November 6, 2023.
John Kiely and Ted Nark are also part of the Board of Directors, both joining in 2023. They are 66 years old and have been Director/Board Members since November 6, 2023.
Gautam Patel has been a Director/Board Member since 2023, bringing a fresh perspective to the company. He is 51 years old and has been a Director/Board Member since November 6, 2023.
Chirag K. Patel has been with the company for a long time, joining in 2001. He is 58 years old and has been a Director/Board Member since December 31, 2001.
Shlomo Yanai and Chintu Patel are the other two members of the Board of Directors. Shlomo Yanai is 72 years old and has been a Director/Board Member since November 6, 2023. Chintu Patel has been the Chairman since 2018 and is 53 years old.
A unique perspective: Masshealth Member Services
Here is a list of the Board of Directors:
- Deborah Autor (Director/Board Member since 2023)
- J. Buchi (Director/Board Member since 2023)
- Jeffrey George (Director/Board Member since 2023)
- John Kiely (Director/Board Member since 2023)
- Paul Meister (Chairman since 2023)
- Ted Nark (Director/Board Member since 2023)
- Gautam Patel (Director/Board Member since 2023)
- Chirag K. Patel (Director/Board Member since 2001)
- Shlomo Yanai (Director/Board Member since 2023)
- Chintu Patel (Chairman since 2018)
Comparisons and Updates
Amneal Pharmaceuticals can be analyzed alongside other similar companies, such as AMRX, using key performance metrics.
Comparing Amneal to AMRX allows us to see how their financials and operations stack up against each other.
In this comparison, we can select up to 4 stocks to analyze, giving us a more comprehensive view of the industry.
Compare To AMRX
If you're looking to analyze similar companies to AMRX, you can select up to 4 stocks for comparison using key performance metrics.
Selecting similar companies can help you understand how AMRX stacks up against its peers. This can be particularly useful for investors looking to diversify their portfolios or identify potential trends.
To get started, simply select up to 4 stocks to compare with AMRX. This will give you a side-by-side comparison of key performance metrics.
For your interest: Private Investor Looking for Projects to Fund
Updates
The latest updates in the world of [topic] are worth noting.

In the past year, a new study found that [specific statistic] users have adopted [new technology or feature].
The findings of this study have significant implications for businesses looking to stay ahead in the market.
One notable example is [company name], which has seen a [percentage] increase in sales since implementing [new technology or feature].
This trend is expected to continue as more users become familiar with [new technology or feature].
Another update worth mentioning is the [specific development] of [new product or service].
This development has the potential to revolutionize the industry and make [specific task] easier and more efficient.
As of now, [new product or service] is still in its testing phase, but early results are promising.
Intriguing read: Meta Announces Ai Users
Frequently Asked Questions
What is the lawsuit against Amneal Pharmaceuticals?
Amneal Pharmaceuticals is facing a lawsuit alleging failure to monitor and report suspicious opioid orders. The lawsuit claims the company did not take adequate steps to prevent opioid diversion and misuse.
Featured Images: pexels.com


